临床试验/NCT04947683

NCT04947683已完成不适用

Patient Journey With Advanced Lung Cancer Positive for ALK Fusion in Brazil

Latin American Cooperative Oncology Group5 个研究点分布在 1 个国家目标入组 101 人开始时间: 2020年4月6日最近更新: 2023年8月2日

适应症

试验速览

阶段: 不适用
状态: 已完成
发起方: Latin American Cooperative Oncology Group
入组人数: 101
试验地点: 5
主要终点: - Describe the treatment sequencing of ALK positive advanced NSCLC in a real-world setting.

研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

Observational, retrospective cohort study that will include patients diagnosed with NSCLC and ALK rearrangement between January 2015 and December 2020.

研究设计

研究类型: Observational
观察模型: Other
时间视角: Retrospective

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Patients older than 18 years;
•Newly diagnosed advanced stage IIIB-IV NSCLC (AJCC 8th edition) or locally advance/distant relapse in the period of January 2015 to December
•NSCLC with pathological confirmation of ALK rearrangement by immunohistochemistry, fluorescent in situ hybridization (FISH) or next generation sequencing (NGS);
•ECOG 0-4;
•Patients with CNS metastases are also considered eligible, regardless of the initial treatment instituted.

排除标准

•Incomplete medical chart in terms of date of diagnosis, ALK test results and outcomes

结局指标

主要结局

- Describe the treatment sequencing of ALK positive advanced NSCLC in a real-world setting.

时间窗: December of 2020

- Describe the timelines from the appearance of symptoms, histopathological diagnosis, application of the molecular test, and start of treatment.

时间窗: December of 2020

次要结局

- Estimate the progression-free survival of first-line treatment, and other subsequent lines;(December of 2020)

研究者

发起方

Latin American Cooperative Oncology Group

申办方类型

Other

责任方

Sponsor

研究点 (5)

Loading locations...

相似试验

已完成

不适用

Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS)Non-Small Cell Lung Cancer

NCT02679170Pfizer692

Unknown

不适用

the Quality of Life Assessment of Lung Cancer Patients in ChinaLung Cancer

NCT01914120Sun Yat-sen University3,000

已完成

不适用

Management of Advanced Non-Small Cell Lung Cancer (NSCLC) and Clinical Outcomes in Patients Who Received Gefitinib in ThailandLung Cancer

NCT01130961AstraZeneca104

已完成

不适用

A Study of Real-world Treatment Patterns and Outcomes in Chinese Advanced NSCLC Patients Who Previously Received at Least 2 Line TreatmentsNon-small Cell Lung Cancer (NSCLC)

NCT06617390Daiichi Sankyo1,041

终止

不适用

Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) NetworkNon-small Cell Lung Cancer MetastaticSmall Cell Lung Carcinoma

NCT01574300Addario Lung Cancer Medical Institute136